Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.52 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 3/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9894537 | 0.86 | MDM2 (0.68) | MDM2GRIN1GRIN2BNOTUM | |
| SCHEMBL1438308 | 0.82 | MDM2 (0.52) | MDM2GRIN1GRIN2BRXRATGFBR1 | |
| SCHEMBL9893845 | 0.81 | MDM2 (0.79) | MDM2NOTUM | |
| SCHEMBL9894004 | 0.81 | MDM2 (0.67) | MDM2TDP2NOTUM | |
| SCHEMBL1443242 | 0.81 | MDM2 (0.52) | MDM2GRIN1GRIN2BMETTGFBR1 | |
| SCHEMBL27862822 | 0.80 | MDM2 (0.52) | MDM2TDP2PDGFRBPDGFRAP2RX7 | |
| SCHEMBL1437257 | 0.79 | MDM2 (0.65) | MDM2TDP2GRIN1GRIN2BP2RX7 | |
| SCHEMBL9893656 | 0.79 | MDM2 (0.63) | MDM2TDP2NOTUM | |
| SCHEMBL1437227 | 0.79 | MDM2 (0.67) | MDM2NOTUM | |
| SCHEMBL1436911 | 0.79 | MDM2 (0.64) | MDM2TDP2P2RX7NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574785-A | Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators | NOVARTIS AG | 2012-07-11 | — | — | CN | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885TDP2 948/4885RET 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.